Cargando…
Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial
BACKGROUND: The Systolic Blood Pressure Intervention Trial (SPRINT) showed that targeting a systolic blood pressure (SBP) of ≤ 120 mm Hg (intensive treatment) reduced cardiovascular disease (CVD) events compared to SBP of ≤ 140 mm Hg (standard treatment); however, it is unclear if this effect is sim...
Autores principales: | Still, Carolyn H, Rodriguez, Carlos J, Wright, Jackson T, Craven, Timothy E, Bress, Adam P, Chertow, Glenn M, Whelton, Paul K, Whittle, Jeffrey C, Freedman, Barry I, Johnson, Karen C, Foy, Capri G, He, Jiang, Kostis, John B, Lash, James P, Pedley, Carolyn F, Pisoni, Roberto, Powell, James R, Wall, Barry M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861531/ https://www.ncbi.nlm.nih.gov/pubmed/28985268 http://dx.doi.org/10.1093/ajh/hpx138 |
Ejemplares similares
-
Monotherapy treatment with chlorthalidone or amlodipine in the systolic blood pressure intervention trial (SPRINT)
por: Vakil, Deep, et al.
Publicado: (2021) -
Is Medication Adherence Predictive of Cardiovascular Outcomes and Blood Pressure Control? The Systolic Blood Pressure Intervention Trial (SPRINT)
por: Glasser, Stephen P, et al.
Publicado: (2021) -
The Association between the Montreal Cognitive Assessment and Functional Activity Questionnaire in the Systolic Blood Pressure Intervention Trial (SPRINT)
por: Still, Carolyn H, et al.
Publicado: (2018) -
The impact of central IRB's on informed consent readability and trial adherence in SPRINT
por: Tamariz, Leonardo, et al.
Publicado: (2019) -
APOL1 Renal-Risk Variants Do Not Associate With Incident Cardiovascular Disease or Mortality in the Systolic Blood Pressure Intervention Trial
por: Freedman, Barry I., et al.
Publicado: (2017)